MCID: RDC006
MIFTS: 42

Red Cell Aplasia

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Red Cell Aplasia

Summaries for Red Cell Aplasia

MalaCards based summary : Red Cell Aplasia is related to transient erythroblastopenia of childhood and large granular lymphocyte leukemia. An important gene associated with Red Cell Aplasia is EPO (Erythropoietin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Phenytoin and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are Increased shRNA abundance and immune system

Related Diseases for Red Cell Aplasia

Diseases related to Red Cell Aplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 471)
# Related Disease Score Top Affiliating Genes
1 transient erythroblastopenia of childhood 34.2 KITLG EPO
2 large granular lymphocyte leukemia 31.3 STAT3 IL2RA
3 chronic graft versus host disease 30.8 IL2RA ALB
4 hepatitis a 30.5 IL2 IFNA1 ALB
5 t-cell large granular lymphocyte leukemia 30.4 STAT3 IL2RA IL2
6 myelofibrosis 30.4 STAT3 IL2RA IFNA1 EPO
7 myasthenia gravis 30.4 IL2 HLA-DQB1 HLA-B
8 thrombocytosis 30.3 KITLG EPO ALB
9 sickle cell anemia 30.3 KITLG EPO ALB
10 lymphoproliferative syndrome 30.2 STAT3 IL2RA IL2
11 autoimmune enteropathy 30.2 STAT3 IL2RA
12 lung abscess 30.1 STAT3 ALB
13 viral hepatitis 30.1 IL2 IFNA1 HLA-DRB1 ALB
14 leprosy 3 30.0 IL2 HLA-DRB1 ALB
15 acute disseminated encephalomyelitis 29.9 HLA-DRB1 HLA-DQB1 HLA-B
16 myeloproliferative neoplasm 29.8 STAT3 KITLG IFNA1 EPO
17 b-cell expansion with nfkb and t-cell anergy 29.7 TRB IL2RA IL2
18 systemic mastocytosis 29.7 KITLG IL2RA IFNA1
19 myeloma, multiple 29.7 STAT3 IL2 IFNA1 EPO ALB
20 hypothyroidism 29.7 STAT3 IL2 IFNA1 ALB
21 porphyria 29.7 TF EPO ALB
22 pure red-cell aplasia 29.6 TRB TF STAT3 OXA1L IL2RA IL2
23 arthritis 29.6 STAT3 HLA-DRB1 HLA-DQB1 HLA-B ALB
24 graft-versus-host disease 29.6 IL2 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
25 diphtheria 29.6 IL2RA IL2 ALB
26 hypereosinophilic syndrome 29.6 STAT3 IL2RA IL2 IFNA1
27 thrombocytopenia 29.5 STAT3 KITLG IL2 IFNA1 EPO ALB
28 hairy cell leukemia 29.5 IL2RA IL2 IFNA1
29 leukemia, chronic myeloid 29.5 STAT3 KITLG IFNA1 EPO
30 autoimmune hepatitis 29.5 IFNA1 HLA-DRB1 HLA-DQB1 HLA-A ALB
31 human immunodeficiency virus type 1 29.4 IL2 IFNA1 HLA-B HLA-A
32 end stage renal failure 29.4 TF IL2RA IL2 EPO ALB
33 tetanus 29.4 IL2RA IL2 HLA-A ALB
34 liver cirrhosis 29.4 TF IFNA1 HLA-DRB1 ALB
35 crohn's disease 29.4 STAT3 IL2 HLA-DRB1 ALB
36 severe cutaneous adverse reaction 29.4 HLA-DRB1 HLA-DQB1 HLA-B HLA-A ALB
37 deficiency anemia 29.3 TF KITLG IFNA1 HLA-B EPO ALB
38 sclerosing cholangitis 29.3 IL2 HLA-DRB1 HLA-B ALB
39 cholangitis 29.3 IL2 HLA-DRB1 HLA-B ALB
40 porphyria cutanea tarda 29.3 TF HLA-A EPO ALB
41 myelodysplastic syndrome 29.3 STAT3 KITLG IL2 HLA-DRB1 HLA-A EPO
42 measles 29.3 IL2RA IL2 IFNA1 HLA-DRB1 HLA-A
43 juvenile rheumatoid arthritis 29.2 IL2RA IL2 HLA-DRB1 HLA-DQB1 ALB
44 immune deficiency disease 29.1 IL2RA IL2 IFNA1 HLA-B HLA-A
45 hemochromatosis, type 1 29.0 TF HLA-B HLA-A EPO ALB
46 lymphoma, non-hodgkin, familial 29.0 STAT3 KITLG IL2RA IL2 HLA-DRB1 HLA-A
47 acquired immunodeficiency syndrome 29.0 IL2RA IL2 IFNA1 HLA-B EPO ALB
48 leukemia, acute myeloid 28.9 STAT3 KITLG IL2 HLA-A EPO ALB
49 herpes zoster 28.9 IL2 IFNA1 HLA-DRB1 HLA-B HLA-A
50 pulmonary tuberculosis 28.9 IL2RA IL2 HLA-DRB1 HLA-DQB1 ALB

Graphical network of the top 20 diseases related to Red Cell Aplasia:



Diseases related to Red Cell Aplasia

Symptoms & Phenotypes for Red Cell Aplasia

GenomeRNAi Phenotypes related to Red Cell Aplasia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 8.92 EPO HLA-B HLA-DQB1 OXA1L

MGI Mouse Phenotypes related to Red Cell Aplasia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.28 ALB EPO FLVCR1 HLA-DQB1 IL2 IL2RA

Drugs & Therapeutics for Red Cell Aplasia

Drugs for Red Cell Aplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
4
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
5 Sodium Channel Blockers Phase 4
6 Anticonvulsants Phase 4
7 Diuretics, Potassium Sparing Phase 4
8 Calcineurin Inhibitors Phase 4
9
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
10
tannic acid Approved Phase 3 1401-55-4
11
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
12
Iron Approved, Experimental Phase 3 7439-89-6, 15438-31-0 23925 27284
13
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
14
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
15
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
16
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
17
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
18
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
19 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
20
Mycophenolic acid Approved Phase 3 24280-93-1 446541
21
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
22 Iron Chelating Agents Phase 2, Phase 3
23 Chelating Agents Phase 2, Phase 3
24 Nutrients Phase 3
25 Ferric Oxide, Saccharated Phase 3
26 Trace Elements Phase 3
27 Micronutrients Phase 3
28 Hematinics Phase 3
29 Epoetin alfa Phase 3 113427-24-0
30 Anti-Infective Agents Phase 3
31 Antibiotics, Antitubercular Phase 3
32 Anti-Bacterial Agents Phase 3
33 Antifungal Agents Phase 3
34 Alkylating Agents Phase 3
35 Antirheumatic Agents Phase 3
36 Antiemetics Phase 3
37 Methylprednisolone Acetate Phase 3
38 Gastrointestinal Agents Phase 3
39 Antitubercular Agents Phase 3
40 Hormone Antagonists Phase 3
41 Neuroprotective Agents Phase 3
42 Dermatologic Agents Phase 3
43 Cyclosporins Phase 3
44 Protective Agents Phase 3
45 Anti-Inflammatory Agents Phase 3
46 Antineoplastic Agents, Hormonal Phase 3
47 Autonomic Agents Phase 3
48 glucocorticoids Phase 3
49 Hormones Phase 3
50
rituximab Approved Phase 2 174722-31-7 10201696

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Research of Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Produced by Immunobiological Technology Institute (Bio-Manguinhos) From Oswaldo Cruz Foundation (Bio-Manguinhos / Fiocruz) Unknown status NCT02648126 Phase 4
2 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
3 Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03540472 Phase 4 tacrolimus
4 Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03364764 Phase 4 Sirolimus
5 Tacrolimus Treatment for Refractory Autoimmune Cytopenia Recruiting NCT03918265 Phase 4 Tacrolimus
6 Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal Anemia Unknown status NCT00238043 Phase 3 Biogeneric Epoetin
7 A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study Unknown status NCT02173951 Phase 2, Phase 3 Deferiprone
8 A Randomized, Multi-Center, Open Label Trial to Establish the Therapeutic Equivalence Between GerEpo and Eprex® and to Determine the Long Term Safety Profile of GerEpo in Patients on Hemodialysis. Completed NCT00229099 Phase 3 GerEPO
9 Assessment of the Use of Intravenous Iron Sucrose to Maintain Haemoglobin Levels and Delay the Onset of Use of Erythropoietic Agents and/or Dialysis in Stage 3/4 Chronic Kidney Disease Completed NCT00202345 Phase 3 Iron sucrose
10 Randomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and Prednisolone Terminated NCT01288131 Phase 3 Cyclosporine combine with mycophenolate mofetil;Cyclophosphamide + pred
11 A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer Terminated NCT00246597 Phase 3 epoetin alfa
12 Therapeutic Use of the Amino Acid Leucine in the Treatment of Transfusion-Dependent Diamond Blackfan Anemia Patients Unknown status NCT02386267 Phase 2 L-leucine
13 An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients With Chronic Kidney Disease Completed NCT00314795 Phase 2 Peginesatide
14 A Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia Completed NCT00229619 Phase 2 Rituximab
15 A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity Completed NCT01044186 Phase 2 ICL670
16 Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
17 Treatment of Diamond Blackfan Anemia With Antithymocyte Globulin and Cyclosporine A Completed NCT00001749 Phase 2 Antithymocyte globulin;Cyclosporine
18 The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS): A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Clinical Trial. Completed NCT00336466 Phase 2 Human recombinant erythropoietin
19 A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS) Completed NCT00072969 Phase 2 Daclizumab
20 B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2 Methimazole;Rituximab
21 A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS) Completed NCT00217594 Phase 2 Alemtuzumab (Campath)
22 A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-MAID) Recruiting NCT03214354 Phase 2 Alemtuzumab;Sirolimus
23 Phase I/II, Open Label Study to Determine Safety of Trifluoperazine (TFP) in Adults With Red Blood Cell Transfusion-Dependent Diamond Blackfan Anemia Recruiting NCT03966053 Phase 1, Phase 2 Trifluoperazine
24 Phase I/II, Open-Label Study to Determine Safety and Efficacy of Sotatercept (ACE-011) in Adults With Red Blood Cell Transfusion- Dependent Diamond Blackfan Anemia Recruiting NCT01464164 Phase 1, Phase 2 Sotatercept;Sotatercept with prednisone boost
25 A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
26 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
27 Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals With Higher Risk of Transplant Failure Recruiting NCT02105766 Phase 2 Alemtuzumab;Sirolimus;Cyclophosphamide;Pentostatin
28 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-Cells Recruiting NCT01174108 Phase 2
29 The Use of Novel Therapies to Reconstitute Blood Cell Production and Promote Organ Performance Using Bone Marrow Failure as a Model: a Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia Active, not recruiting NCT01362595 Phase 1, Phase 2 leucine
30 A Pilot Study of Recombinant Humanized Anti-Interleukin (IL-2) Receptor Antibody (Daclizumab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia Terminated NCT00001962 Phase 2 Daclizumab
31 A Phase II Study of Alemtuzumab in Autoimmune Cytopenias Terminated NCT00472433 Phase 2 Alemtuzumab
32 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
33 Screening Protocol and Longitudinal Study of Bone Marrow Failure Syndromes and Cytopenias Unknown status NCT00315419
34 An Active Safety Surveillance Plan to Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) Among Patients Receiving Epoetin Alfa Therapy or Other Recombinant Erythropoietins Completed NCT00211029
35 An Active Safety Surveillance Plan to Conduct Serologic Testing for Anti-erythropoietin Antibodies and Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) Among Patients Receiving Epoetin Alfa or Another Erythropoietin Completed NCT00210951
36 Observational, Multicenter Study of Subjects With Pure Red Cell Aplasia Associated With r-HuEPO Treatment Completed NCT00211042
37 Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders Completed NCT00005893 anti-thymocyte globulin;busulfan;cyclophosphamide
38 Retrospective Case-control Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa Completed NCT00211068 No intervention
39 Stem Cell Transplantation (SCT) for Genetic Diseases Completed NCT00004378
40 A Prospective, Immunogenicity Surveillance Registry (PRIMS) to Estimate the Incidence of Erythropoietin Antibody-Mediated Pure Red Cell Aplasia Among Subjects With Chronic Renal Failure and Subcutaneous Exposure to Recombinant Erythropoietin Products Completed NCT00391287
41 Cytokine Gene Polymorphisms in Bone Marrow Failure Completed NCT00085670
42 Audit of the Effect of Changing From IV to SC Administration of Erythropoiesis Stimulating Agents in Haemodialysis Patients - Real Life Clinical Experience Completed NCT00382044 Eprex; Neorecormon; Aranesp
43 High-Tc Susceptometer to Monitor Transfusional Iron Overload (NSR Device) Completed NCT01241357
44 Diamond Blackfan Anemia Registry (DBAR) Recruiting NCT00106015
45 Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study Recruiting NCT00027274
46 POST-AUTHORISATION SAFETY COHORT OBSERVATION OF RETACRIT (EPOETIN ZETA) ADMINISTERED SUBCUTANEOUSLY FOR THE TREATMENT OF RENAL ANAEMIA (PASCO II) Active, not recruiting NCT01543477
47 An Observational Study of Subjects Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies Withdrawn NCT00210977 No intervention
48 Compassionate Use of the CliniMACS® CD34 Reagent System for Patients Requiring a Post Hematopoietic Stem Cell Transplant Boost of Donor Hematopoietic Stem Cells Withdrawn NCT01660347

Search NIH Clinical Center for Red Cell Aplasia

Genetic Tests for Red Cell Aplasia

Anatomical Context for Red Cell Aplasia

MalaCards organs/tissues related to Red Cell Aplasia:

40
Bone, Bone Marrow, T Cells, Kidney, B Cells, Liver, Myeloid

Publications for Red Cell Aplasia

Articles related to Red Cell Aplasia:

(show top 50) (show all 1955)
# Title Authors PMID Year
1
Anti-erythropoietin antibodies followed by endogenous erythropoietin production in a dialysis patient. 54 61
20091055 2010
2
Pure red cell aplasia associated with Good's syndrome accompanied by decreased stem cell factor production in the bone marrow. 54 61
20190468 2010
3
Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report. 54 61
19830190 2009
4
Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study. 54 61
19164318 2009
5
[Erythropoiesis-stimulating agents in chronic kidney disease: which route of administration?]. 54 61
19255962 2009
6
Pure red cell aplasia due to follow-on epoetin. 54 61
18547998 2008
7
Epoetin-associated pure red cell aplasia: past, present, and future considerations. 54 61
18482185 2008
8
[Report of a case with pure red cell aplasia following recombinant human erythropoietin treatment]. 54 61
19099822 2008
9
Pure red cell aplasia induced by erythropoiesis-stimulating agents. 54 61
18178785 2008
10
Epoetin-induced pure red cell aplasia: diagnosis and treatment. 54 61
18089975 2007
11
A potent erythropoietin-mimicking human antibody interacts through a novel binding site. 54 61
17620453 2007
12
Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. 54 61
17662888 2007
13
[Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease]. 54 61
17571584 2007
14
Pure red cell aplasia caused by antibody to erythropoietin successfully treated by cyclosporine administration. 54 61
16947314 2007
15
Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia. 54 61
17164586 2007
16
Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis. 54 61
16449549 2006
17
Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients. 54 61
16249199 2006
18
Resistant pure red cell aplasia after allogeneic bone marrow transplantation with major ABO mismatch treated by purified CD34+ cell infusion. 54 61
16405438 2006
19
Epoetin alfa: basic biology and clinical utility in cancer patients. 54 61
16336085 2005
20
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. 54 61
16099877 2005
21
Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone. 54 61
16046510 2005
22
Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. 54 61
16105053 2005
23
Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)? 54 61
16079325 2005
24
The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. 54 61
15882278 2005
25
Rapid resolution of EPO-induced pure red cell aplasia after a course of immunoadsorption therapy using protein A columns. 54 61
15957124 2005
26
Optimizing anaemia management with subcutaneous administration of epoetin. 54 61
15958820 2005
27
Factors influencing the immunogenicity of therapeutic proteins. 54 61
15958824 2005
28
What is antibody-mediated pure red cell aplasia (PRCA)? 54 61
15827056 2005
29
Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. 54 61
15827053 2005
30
Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. 54 61
15824129 2005
31
Antibody-mediated side effects of recombinant proteins. 54 61
15767028 2005
32
Epoetin-induced autoimmune pure red cell aplasia. 54 61
15938038 2005
33
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. 54 61
15792923 2005
34
Importance of biologic follow-ons: experience with EPO. 54 61
15792912 2005
35
Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. 54 61
15522068 2004
36
Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done? 54 61
15496566 2004
37
Prolonged course of pure red cell aplasia after erythropoietin therapy. 54 61
15458518 2004
38
[Pure red cell aplasia as a complication of treatment with recombinant human erythropoietin]. 54 61
15690716 2004
39
Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. 54 61
15466278 2004
40
Expression, bioactivity, and clinical assessment of recombinant feline erythropoietin. 54 61
15524322 2004
41
Antierythropoietin antibody-induced pure red cell aplasia: posttransplant evolution. 54 61
15138876 2004
42
Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis. 54 61
15284306 2004
43
Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia. 54 61
15252175 2004
44
Successful treatment of pure red cell aplasia with cyclosporin A and erythropoietin after thymectomy in a 88-year old woman. 54 61
15194553 2004
45
Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. 54 61
15172775 2004
46
Pure red cell aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins. 54 61
15009075 2004
47
Clinical efficacy and safety of recombinant canine erythropoietin in dogs with anemia of chronic renal failure and dogs with recombinant human erythropoietin-induced red cell aplasia. 54 61
14765736 2004
48
Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. 54 61
15056991 2004
49
The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. 54 61
14659922 2003
50
Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. 54 61
14608000 2003

Variations for Red Cell Aplasia

Expression for Red Cell Aplasia

Search GEO for disease gene expression data for Red Cell Aplasia.

Pathways for Red Cell Aplasia

Pathways related to Red Cell Aplasia according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.17 STAT3 KITLG IL2RA IL2 IFNA1 HLA-DRB1
2
Show member pathways
12.89 KITLG IL2RA IL2 IFNA1 HLA-B HLA-A
3 12.73 STAT3 KITLG IL2RA IL2 IFNA1 EPO
4 12.71 IFNA1 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
5
Show member pathways
12.65 IL2RA IL2 IFNA1 HLA-DRB1 HLA-DQB1 HLA-B
6
Show member pathways
12.55 TRB IL2RA IL2 HLA-DRB1 HLA-DQB1
7
Show member pathways
12.49 TRB STAT3 IL2RA IL2 HLA-DRB1 HLA-DQB1
8 12.48 STAT3 KITLG IL2RA IL2 IFNA1
9
Show member pathways
12.45 IFNA1 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
10
Show member pathways
12.4 IL2 IFNA1 HLA-B HLA-A
11
Show member pathways
12.3 IL2RA IL2 HLA-DRB1 HLA-DQB1
12
Show member pathways
12.26 STAT3 IL2RA IL2 IFNA1 EPO
13
Show member pathways
12.26 STAT3 IL2RA IL2 IFNA1 HLA-DRB1 HLA-DQB1
14
Show member pathways
12.14 KITLG IL2RA IL2 IFNA1 HLA-B HLA-A
15 12.07 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
16 12.05 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
17 11.97 IL2RA IL2 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
18
Show member pathways
11.95 STAT3 IL2RA IL2
19 11.94 STAT3 KITLG ALB
20
Show member pathways
11.91 STAT3 IL2RA IL2
21 11.9 KITLG IL2RA IL2 EPO
22 11.85 TF STAT3 EPO
23 11.78 STAT3 IL2RA IL2 IFNA1 EPO
24 11.72 KITLG IL2RA HLA-DRB1 HLA-DQB1 EPO
25
Show member pathways
11.71 TRB HLA-DRB1 HLA-DQB1
26
Show member pathways
11.57 IL2RA IL2 HLA-A
27 11.46 TF KITLG EPO
28 11.19 TRB IL2 HLA-DRB1
29
Show member pathways
11.15 TRB STAT3 IL2RA IL2 HLA-DRB1 HLA-A
30 11 STAT3 IL2RA IL2 HLA-DRB1

GO Terms for Red Cell Aplasia

Cellular components related to Red Cell Aplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.87 TF KITLG IL2 IFNA1 HLA-B EPO
2 cell surface GO:0009986 9.63 TF IL2RA HLA-DRB1 HLA-B HLA-A EPO
3 MHC class II protein complex GO:0042613 9.37 HLA-DRB1 HLA-DQB1
4 MHC class I protein complex GO:0042612 9.26 HLA-B HLA-A
5 ER to Golgi transport vesicle membrane GO:0012507 9.26 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.92 HLA-DRB1 HLA-DQB1 HLA-B HLA-A

Biological processes related to Red Cell Aplasia according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.92 STAT3 KITLG IL2 EPO ALB
2 cytokine-mediated signaling pathway GO:0019221 9.86 STAT3 IL2RA IL2 IFNA1
3 immune system process GO:0002376 9.8 IL2RA IL2 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.69 STAT3 IL2 EPO
5 type I interferon signaling pathway GO:0060337 9.67 IFNA1 HLA-B HLA-A
6 immune response GO:0006955 9.63 IL2RA IL2 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
7 positive regulation of T cell differentiation GO:0045582 9.6 IL2RA IL2
8 regulation of regulatory T cell differentiation GO:0045589 9.59 IL2RA IL2
9 inflammatory response to antigenic stimulus GO:0002437 9.58 IL2RA HLA-DRB1
10 erythrocyte maturation GO:0043249 9.58 FLVCR1 EPO
11 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.57 HLA-DRB1 HLA-DQB1
12 interleukin-2-mediated signaling pathway GO:0038110 9.55 IL2RA IL2
13 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.54 HLA-B HLA-A
14 negative regulation of lymphocyte proliferation GO:0050672 9.48 IL2RA IL2
15 protection from natural killer cell mediated cytotoxicity GO:0042270 9.46 HLA-B HLA-A
16 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.43 HLA-DRB1 HLA-DQB1
17 positive regulation of activated T cell proliferation GO:0042104 9.43 IL2RA IL2 EPO
18 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.4 HLA-DRB1 HLA-DQB1
19 regulation of T cell homeostatic proliferation GO:0046013 9.37 IL2RA IL2
20 interferon-gamma-mediated signaling pathway GO:0060333 9.26 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
21 antigen processing and presentation GO:0019882 8.92 HLA-DRB1 HLA-DQB1 HLA-B HLA-A

Molecular functions related to Red Cell Aplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 KITLG IL2 IFNA1 EPO
2 MHC class II receptor activity GO:0032395 9.16 HLA-DRB1 HLA-DQB1
3 peptide antigen binding GO:0042605 8.92 HLA-DRB1 HLA-DQB1 HLA-B HLA-A

Sources for Red Cell Aplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....